NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

A vaccine kept patients free of pancreatic cancer for years, yet new reports say the NIH is advising against mentioning mRNA tech in grants.

Goldman Sachs initiated coverage of Sanofi (SNY) with a Neutral rating and $65 price target While the firm sees Sanofi emerging as a pipeline ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer ...

Electronic reminders to encourage older adults in Denmark to get vaccinated against flu may have unintentionally lowered ...

Imagine a previously unknown bug—new to our immune defenses—that suddenly emerged and rapidly spread all over the globe, ...

In February, Turkey agreed to send more eggs to the U.S., where there is an ongoing shortage amid the death of nearly 170M ...

It is important to understand the correlates of protection against SARS-CoV-2 and its variants for future vaccine design ... alveolar damage in severe COVID-19 patients using integrated ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein. The ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...